Robert A. Verhagen
Directeur/Membre du Conseil chez ImmunoBiochem Corp.
Profil
Robert A.
Verhagen is currently a Director at ImmunoBiochem Corp.
Previously, he was the President, Chief Executive Officer & Director at Helix BioPharma Corp.
from 2012 to 2015.
He also held the position of Vice President-Business Development at Spectral Medical, Inc. Verhagen obtained his undergraduate degree and MBA from the University of Alberta.
Postes actifs de Robert A. Verhagen
| Sociétés | Poste | Début |
|---|---|---|
ImmunoBiochem Corp.
 ImmunoBiochem Corp. BiotechnologyHealth Technology ImmunoBiochem Corp. is a biopharmaceutical company founded in 2007, based in Canada. The private company is focused on developing biological therapeutics to address unmet needs in oncology and immuno-oncology. ImmunoBiochem has worked closely with the University of Toronto, one of the world's leading institutions in research and innovation, on some of its novel programs. The Canadian company uses high-throughput functional screens, bioinformatics, and AI/ML to discover novel tumor targets in the tumor microenvironment, particularly in the cancer cell secretome. The company is a Johnson & Johnson Innovation JLABS alumnus and is headquartered in the heart of Canada's largest biomedical research hub. | Directeur/Membre du Conseil | - |
Anciens postes connus de Robert A. Verhagen
| Sociétés | Poste | Fin |
|---|---|---|
| HELIX BIOPHARMA CORP. | Directeur Général | 01/11/2015 |
| SPECTRAL MEDICAL INC. | Corporate Officer/Principal | - |
Formation de Robert A. Verhagen
| University of Alberta | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SPECTRAL MEDICAL INC. | Health Technology |
| HELIX BIOPHARMA CORP. | Health Technology |
| Entreprise privées | 1 |
|---|---|
ImmunoBiochem Corp.
ImmunoBiochem Corp. BiotechnologyHealth Technology ImmunoBiochem Corp. is a biopharmaceutical company founded in 2007, based in Canada. The private company is focused on developing biological therapeutics to address unmet needs in oncology and immuno-oncology. ImmunoBiochem has worked closely with the University of Toronto, one of the world's leading institutions in research and innovation, on some of its novel programs. The Canadian company uses high-throughput functional screens, bioinformatics, and AI/ML to discover novel tumor targets in the tumor microenvironment, particularly in the cancer cell secretome. The company is a Johnson & Johnson Innovation JLABS alumnus and is headquartered in the heart of Canada's largest biomedical research hub. | Health Technology |
